source
- FDA adds peptide-focused physicians to advisory panel, raising conflict-of-interest concernsThe FDA announced eight new members for a committee that will advise on whether compounding pharmacies can produce certain peptides. Most of the appointees are physicians or pharmacists who run bu…
- Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacksZymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…